Seroprevalencia anti-SARS-CoV-2 en personal administrativo del Instituto Mexicano del Seguro Social / Anti-SARS-CoV-2 seroprevalence in administrative staff of the Mexican Institute for Social Security
Keywords:
COVID-19, SARS-CoV-2, IgG, Personal Administrativo, Seroprevalencia / COVID-19, Administrative Personnel, SeroprevalenceAbstract
Resumen
Introducción: los sujetos asintomáticos, la falta de pruebas diagnósticas y, en países como México, el método de vigilancia epidemiológica no permiten establecer el número real de contagios en la pandemia de COVID-19. El personal de salud de primera línea y otros grupos con actividades prioritarias son de alto riesgo. Se incluyeron trabajadores administrativos en contacto con personal de salud en las unidades hospitalarias del Instituto Mexicano del Seguro Social (IMSS).
Objetivo: identificar la seroprevalencia de anticuerpos contra SARS-CoV-2 en personal administrativo del IMSS que no atiende a enfermos.
Material y métodos: se incluyeron 76 individuos a los cuales se les midieron los anticuerpos IgG contra la nucleoproteína del SARS-CoV-2. También se les aplicó un cuestionario para identificar factores de riesgo.
Resultados: se incluyeron 76 participantes (39 hombres, 51.7%), con una mediana de 42 años de edad. Fueron positivos 29 de 76 sujetos (38.2%), cuya mediana de edad fue de 38 años (rango 18-69 años); 15 hombres y 14 mujeres. Hubo mayor porcentaje de sujetos positivos menores de 45 años (n = 20, 84.2%) que aquellos de edad ≥ 45 años (n = 9, 25%), con una RM de 3 (IC 95% 1.13-7.96, p = 0.03). No hubo diferencia estadísticamente significativa respecto al tipo de comorbilidad.
Conclusiones: la prevalencia identificada muestra una circulación importante del virus en el personal administrativo.
Abstract
Background: Asymptomatic subjects, the lack of diagnostic tests and, in countries like Mexico, the epidemiological surveillance method does not allow to establish the real number of infections in the COVID-19 pandemic. Frontline health personnel, as well as other groups related to priority activities are considered of high risk. We included administrative workers in contact with health personnel in the hospital units of the Mexican Institute for Social Security (IMSS, according to its initials in Spanish).
Objective: To identify the seroprevalence of antibodies to SARS-CoV-2 in IMSS’ administrative staff who does not treat patients.
Material and methods: 76 volunteer participating individuals were incluided; IgG antibodies against the SARS-CoV-2 nucleoprotein were measured. A questionnaire was administered to the participants in order to identify possible risk factors.
Results: 76 participants were included (39 men, 51.7%), with a median age of 42 years. 29 out of 76 subjects (38.2%), whose median age was 38 years (range 18-69 years); 15 men (51.7%), and 14 women (48.3%). A higher percentage of positive subjects under 45 years of age (n = 20, 84.2%) was observed than those aged 45 or over (n = 9, 25%), with an OR of 3 (95% CI 1.13-7.96, p = 0.03). No statistically significant difference was found regarding the type of comorbidity.
Conclusions: The prevalence identified shows an important circulation of the virus in the administrative staff.
Downloads
References
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-33. doi: 10.1056/NEJMoa2001017.
Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol. 2015;23(8):468-78. doi:10.1016/j. tim.2015.06.003.
Wang X, Rong W. Predicting acute respiratory infection in Chinese healthy individuals: A effective way of patient care. Journal of King Saud University - Science. 2020;32(1):1065-8. doi:10.1016/j.jksus.2019.10.002.
Read JM, Bridgen JRE, Cummings DAT, Ho A, Jewell CP. Novel coronavirus 2019-nCoV (COVID-19): early estimation of epidemiological parameters and epidemic size estimates. Philos Trans R Soc Lond B Biol Sci. 2021;19;376(1829):20200265. doi: 10.1098/rstb.2020.0265.
Ahmed, T, Noman, M, Almatroudi A, Shahid M, Khurshid M, Tariq F, et al. Coronavirus disease 2019 assosiated pneumonia in China: Current status and future prospects. Preprints. 2020; 202002.0358. doi: 10.20944/preprints202002.0358.v3.
World Health Organization. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update [internet]. Geneva: WHO; 2019. Disponible en: https:// www.who.int/emergencies/diseases/novel-coronavirus- 2019/ situation-reports/ [consultado el 20 de diciembre de 2021].
Secretaría de Salud. Informes Epidemiológicos de la situación de COVID-19 en México 2021. Situación epidemiológica de COVID-19 en México [internet]. México: Secretaría de Salud; 2021. Disponible en: https://www.gob.mx/salud/ documentos/informes-epidemiologicos-de-la-situacion-de-covid19-en-mexico-2021 [consultado el 10 de febrero de 2022].
Yang Y, Yang M, Yuan J, Wang F, Wang Z, Li J, et al. Laboratory Diagnosis and Monitoring the Viral Shedding of SARS-CoV-2 Infection. Innovation. 2020;1(3):1-6. doi:10.1016/j. xinn.2020.100061.
Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020;92 (9):1518-24. doi: 10.1002/jmv.25727.
Lisboa-Bastos M, Tavaziva G, Abidi SK, Campbell JR, Haraoui LP, Johnston JC, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020;1;370:m2516. doi: 10.1136/bmj.m2516.
Liu L, Liu W, Zheng Y, Jiang X, Kou G, Ding J, et al. A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients. Microbes Infect. 2020;22(4-5):206-11. doi: 10.1016/j.micinf.2020.05.008.
Steensels D, Oris E, Coninx L, Nuyens D, Delforge ML, Vermeersch P, et al. Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium. JAMA. 2020;14;324(2):195-7. doi: 10.1001/jama.2020.11160.
Díaz-Salazar C, Sánchez-García A, Rodríguez-Gutiérrez R, Camacho-Ortiz A, Saldívar-Rodríguez D, González-González JG. Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival. BMC Infect Dis. 2021;21(1):835. doi:10.1186/ s12879-021-06550-5.
Martinez-Acuña N, Avalos-Nolazco DM, Rodriguez-Rodriguez DR, Martinez-Liu CG, Galan-Huerta KA, Padilla-Rivas GR, et al. Seroprevalence of anti-sars-cov-2 antibodies in blood donors from nuevo leon state, Mexico, during 2020: A retrospective cross-sectional evaluation. Viruses. 2021;13 (7):1225 doi: 10.3390/v13071225.
Cruz-Arenas E, Cabrera-Ruiz E, Laguna-Barcenas S, Colin-Castro CA, Chavez T, Franco-Cendejas R, et al. Serological prevalence of SARS-CoV-2 infection and associated factors in healthcare workers in a “non-COVID” hospital in Mexico City. PLoS One. 2021;16(8):e0255916. doi: 10.1371/journal. pone.0255916.
Rodríguez-Vidales EP, Garza-Carrillo D, Pérez-Trujillo JJ, Robles-Rodríguez OA, Salinas-Martínez AM, Montes de Oca-Luna R, et al. Prevalence of IgG antibodies induced by the SARS-COV-2 virus in asymptomatic adults in Nuevo Leon, Mexico. J Med Virol. 2021;93(10):5873-9. doi: 10.1002/jmv.27131.
Remes-Troche JM, Ramos-de la Medina A, Manríquez-Reyes M, Martínez-Pérez-Maldonado L, Solis-Gonzalez MA, Hernández Flores KG, et al. Prevalence of SARS-CoV-2 IgG antibodies in a population from Veracruz (Southeastern Mexico). medRxiv. 2020. doi:10.1101/2020.10.19.20215558.
Muñoz-Medina JE, Grajales-Muñiz C, Salas-Lais AG, Fernandes-Matano L, López-Macías C, Monroy-Muñoz IE, et al. Seroprevalence and Neutralizing Activity of IgG Antibodies Against SARS-CoV-2 in Mexico. Microorganisms. 2021;9(4): 850. doi: 10.3390/microorganisms9040850.
Rudberg AS, Havervall S, Månberg A, Falk AJ, Aguilera K, Ng H, et al. SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nat Commun. 2020;11(1):5064. doi:10.1038/s41467-020-18848-0.
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis and treatment of coronavirus disease 2019 (COVID-19): A review, JAMA. 2020;324(8):782-93. doi: 10.1001/jama.2020.12839.
Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al. Antibody test for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020;6(6): CD013652. doi: 10.1002/14651858.CD013652.
Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Shiadeh MN, Esfandyari S, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis, Clin Microbiol Infect. 2021;27(3): 331-40. doi: 10.1016/j.cmi.2020.10.020.
Mansour M, Leven E, Muellers K, Stone K, Mendu DR, Wajnberg A, et.al, Prevalence of SARS-CoV-2 Antibodies among healthcare workers at a tertiary academic Hospital in New York City. J Gen Intern Med. 2020;35(8):2485-6. doi: 10.1007/ s11606-020-05926-8.
Gobierno de la Ciudad de México. Modelo epidemiológico Covid-19 del Gobierno de la Ciudad de México. México Gobierno de la Ciudad de México; 2020: Disponible en: https:// modelo.covid19.cdmx.gob.mx/modelo-epidemico.
Miramontes O. Entendamos el COVID-19 en México. México: Universidad Nacional Autónoma de México; 4 de septiembre de 2020. pp. 1-37. Disponible en http://scifunam.fisica.unam. mx/mir/corona19/covid19.pdf.
Ibarra-Nava I, Cardenas-de la Garza JA, Ruiz-Lozano RE, Salazar-Montalvo RG. Mexico and the COVID-19 Response. Disaster Med Public Health Prep.14(4):e17-18. doi:10.1017/ dmp.2020.260..
World Today News. Sentinel model estimated 104,562 coronavirus cases in Mexico, but UNAM scenarios calculated many more. World Today News; 4 May 2020. Disponible en: https://world-today-news.com/sentinel-model-estimated-104562-coronavirus-cases-in-mexico-but-unam-scenarios-calculated-many-more/
Padilla-Santamaría F, Maya-Franco L, Ferman-Cano F. COVID-19 en México: Panorama Epidemiológico. Revista Cadena de Cerebros. 2020;4(1):31-42. doi: 10.5281/zenodo.3926806.
Ñamendys-Silva SA. Healthcare workers with COVID-19 in Mexico. European Rspiratory Journa. 2020;56(4):1-2. doi: 10.1183/13993003.02885-2020.
Fernández-Rojas MA, Luna-Ruiz Esparza MA, Campos-Romero A, Calva-Espinosa DY, Moreno-Camacho JL, Langle-Martínez AP, et al. Epidemiology of COVID-19 in Mexico: Symptomatic profiles and presymptomatic people. Int J Infect Dis. 2021;104: 572-9. doi:10.1016/j.ijid.2020.12.086.
Downloads
Published
Issue
Section
License
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.
